ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.64
-0.20%
US Tech 100
18,356.40
0.70%
S&P 500
5,320.58
0.26%
US Dollar vs CAD
1.36975
0.04%
Bitcoin
68,085.72
-1.47%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Arcutis Biotherapeutics Inc (ARQT)

  7. Arcutis Biotherapeutics Inc (ARQT) News

ARQT

Arcutis Biotherapeutics (ARQT)

Arcutis Biotherapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARQT
DateTimeSourceHeadlineSymbolCompany
05/20/20244:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
05/17/20242:58PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
05/14/20243:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARQTArcutis Biotherapeutics Inc
05/14/20243:00PMGlobeNewswire Inc.Arcutis Announces First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARQTArcutis Biotherapeutics Inc
05/14/20246:18AMIH Market NewsUS Futures Remain Steady Amid Wall Street Caution Ahead of April PPI ReportNASDAQ:ARQTArcutis Biotherapeutics Inc
05/13/20247:00AMGlobeNewswire Inc.Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic DermatologyNASDAQ:ARQTArcutis Biotherapeutics Inc
05/03/20243:00PMGlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
04/29/20243:00PMGlobeNewswire Inc.Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024NASDAQ:ARQTArcutis Biotherapeutics Inc
04/10/20247:00AMGlobeNewswire Inc.Arcutis Appoints David Topper as Chief Financial OfficerNASDAQ:ARQTArcutis Biotherapeutics Inc
04/05/20243:00PMGlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
04/01/20246:00AMGlobeNewswire Inc.Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® CreamNASDAQ:ARQTArcutis Biotherapeutics Inc
03/28/20247:00AMGlobeNewswire Inc.Arcutis to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ARQTArcutis Biotherapeutics Inc
03/11/20247:00AMGlobeNewswire Inc.Arcutis Promotes Todd Tucker to Chief Human Resources OfficerNASDAQ:ARQTArcutis Biotherapeutics Inc
03/10/20243:00PMGlobeNewswire Inc.Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual MeetingNASDAQ:ARQTArcutis Biotherapeutics Inc
03/09/20243:00PMGlobeNewswire Inc.New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier DysfunctionNASDAQ:ARQTArcutis Biotherapeutics Inc
03/06/20244:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
03/06/20244:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
03/06/20244:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
03/05/20243:00PMGlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
03/04/20244:47PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
03/04/20244:42PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
03/04/20244:40PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
03/04/20243:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARQTArcutis Biotherapeutics Inc
03/04/20243:00PMGlobeNewswire Inc.Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesNASDAQ:ARQTArcutis Biotherapeutics Inc
03/04/20247:00AMGlobeNewswire Inc.Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual MeetingNASDAQ:ARQTArcutis Biotherapeutics Inc
03/01/20243:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
03/01/20243:06PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARQTArcutis Biotherapeutics Inc
02/29/20244:00PMGlobeNewswire Inc.Arcutis to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:ARQTArcutis Biotherapeutics Inc
02/28/202410:30PMGlobeNewswire Inc.Arcutis Announces Pricing of $150 Million Public OfferingNASDAQ:ARQTArcutis Biotherapeutics Inc
02/28/20243:54PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ARQT

Your Recent History

TG
4P0
Appfolio
LSE
51EN
Mitsu Hc Cap 23
BIT
P1VI15
NLBNPIT1VI15 20991231 43...
NYSE
EQC
Equity Commonwealth
USOTC
ESAKF
Essity (GM)
NYSE
BMO
Bank of Montreal
MRTX
XAURBTC
Xaurum
ASX
1ADOA
AdAlta
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved